Main outcome measure
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Archives of Physical Medicine and Rehabilitation
- Spinal cord injury. National Spinal Cord Injury Statistical Center, Univ Alabama, Birmingham2001
- Neurologic recovery after traumatic spinal cord injury.Arch Phys Med Rehabil. 1999; 80: 1391-1396
- The epidemiology of spinal cord injury.in: Stover S.L. DeLisa J.A. Whiteneck G.G. Spinal cord injury clinical outcomes from the model systems. Aspen, Gaithersburg1995: 21-51
- Spinal cord injury.Arch Phys Med Rehabil. 1991; 72: 119-121
- Post-traumatic acute anterior spinal cord syndrome.Paraplegia. 1981; 19: 201-205
- Motor and sensory recovery following incomplete tetraplegia.Arch Phys Med Rehabil. 1994; 75: 306-311
- Recruitment and early treatment in a multicenter study of acute spinal cord injury.Spine. 2001; 26: S58-S67
- Measurements and recovery patterns in a multicenter study of acute spinal cord injury.Spine. 2001; 26: S68-S86
- The Sygen multicenter acute spinal cord injury study.Spine. 2001; 26: S87-S98
- International standards for the neurological classification of spinal cord injury. ASIA, Chicago2002
- A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.N Engl J Med. 1990; 322: 1405-1411
- Pin sensation as a predictor of extensor carpi radialis recovery in spinal cord injury.Arch Phys Med Rehabil. 1993; 74: 14-18
- Motor recovery of patients presenting with motor paralysis and sensory sparing following cervical spinal cord injuries.Paraplegia. 1995; 33: 506-509
- Patient selection for clinical trials.J Neurotrauma. 2003; 20: 477-482
Supported by the Rehabilitation Medicine Scientist Training Program, National Institute of Child Health and Human Development, National Institutes of Health (grant no. 2K12 HD0197-6) and the Christopher Reeve Paralysis Foundation.
A commercial party having a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit upon the author or 1 or more of the authors.
The Fidia Pharmaceutical Corp sponsored the Sygen (GM-1 ganglioside) multicenter trial from which data for this study, a secondary analysis of natural recovery after spinal cord injury, was derived. Geisler and Coleman have received research grants, consulting agreements, or employment from Fidia Pharmaceutical Corp. For the Sygen multicenter clinical trial, Ditunno served on the external monitoring committee mandated by the US Food and Drug Administration for safety monitoring and was paid by Fidia in that capacity.